Last Updated: November 16, 2026

Details for Patent: 8,618,160

« Back to Dashboard


Which drugs does patent 8,618,160 protect, and when does it expire?

Patent 8,618,160 protects QBREXZA and is included in one NDA.

This patent has nine patent family members in six countries.

Summary for Patent: 8,618,160
Title:Topical glycopyrrolate formulations
Abstract:Individually packaged topical formulations comprising about 0.25 to about 6% w/w of glycopyrrolate for the treatment of hyperhidrosis, wherein said wipe is contained within a pouch resistant to leakage. The formulations may further comprise ethanol, a buffering agent and water. In addition, the formulations may further comprise a polymer system comprising a hydrophobic polymer in combination with a hydrophilic polymer.
Inventor(s):Michael Johnston, Robert James Houlden
Assignee: Rose U LLC
Application Number:US12/738,168
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 8,618,160
Patent Claim Types:
see list of patent claims
Use; Dosage form;
Patent landscape, scope, and claims:

US Patent 8,618,160: Glycopyrrolate Hyperhidrosis Wipe Claims, Patent Scope, and Competitive Landscape

US Patent No. 8,618,160 protects a specific topical hyperhidrosis wipe system rather than glycopyrrolate generally. Its core combination requires a glycopyrrolate compound, an approximately 50:50 to 70:30 alcohol-water vehicle, an approximately pH 4.5 buffer at 10-20 mM, packaging in a leakage-resistant pouch, and demonstrated glycopyrrolate degradation of less than 0.5% after three months at 40°C. The patent also covers selected pouch materials, excipients, buffer systems, ethanol concentrations, wipe substrates, and treatment use.

The claim set is closely aligned with the product architecture of Qbrexza, the glycopyrronium tosylate topical cloth approved by the FDA for primary axillary hyperhidrosis. The patent does not, on its face, create a monopoly over all glycopyrronium formulations, all hyperhidrosis treatments, or all topical wipes.

What does US Patent 8,618,160 protect?

The patent protects an individually packaged, chemically stable medicated wipe with defined formulation and packaging parameters.

Claim element Scope
Active ingredient About 0.25% to about 6% w/w glycopyrrolate compound
Indication Treatment or alleviation of hyperhidrosis
Vehicle Alcohol and water in an approximately 50:50 to 70:30 weight ratio
Buffer Maintains pH at about 4.5; concentration of approximately 10-20 mM
Stability Less than 0.5% glycopyrrolate degradation after three months at 40°C
Packaging Individual pouch resistant to leakage
Dependent packaging limitation Inner lining comprising LLDPE
Optional excipients Propylene glycol, preservative, additive
Buffer alternatives Citric acid/sodium citrate or citric acid/tromethamine
Wipe substrate Nonwoven, paper, woven, knitted, tufted, stitched-bonded, or wet-milled felted material
Treatment method Topical application to reduce hyperhidrosis

Claim 1 is the principal composition-and-package claim. Claims 2-8, 10-13 narrow that combination. Claim 9 is a method-of-treatment claim that depends on use of the wipe of claim 1.

How broad is independent claim 1?

Claim 1 has substantial breadth in the identity of the glycopyrrolate compound, wipe substrate, alcohol, and packaging construction. It is narrower in the formulation and stability requirements.

Active ingredient scope

The phrase "glycopyrrolate compound" is broader than a claim limited expressly to glycopyrronium tosylate. Depending on the specification and claim-construction record, it may encompass glycopyrrolate, glycopyrronium salts, solvates, hydrates, and other pharmaceutically acceptable forms.

That breadth is constrained by the requirement that the compound be present in a topical wipe at approximately 0.25% to 6% w/w. A product using a different anticholinergic, such as oxybutynin or sofpironium, would not literally meet this active-ingredient limitation.

Vehicle scope

The alcohol-water ratio is a central limitation. A formulation outside the approximately 50:50 to 70:30 alcohol-water range presents a straightforward noninfringement position if the ratio is measured consistently with the patent specification.

Claim 10 narrows the alcohol to ethanol. Claim 1, however, does not expressly limit the alcohol to ethanol. This creates potential coverage for other pharmaceutically acceptable alcohols if the remaining limitations are met.

Buffer and pH limitations

Claim 1 requires both:

  1. A buffer that maintains pH at approximately 4.5; and
  2. A buffer concentration of approximately 10-20 mM.

A formulation with a pH near 4.5 but no buffering capacity, or with a buffer concentration materially outside 10-20 mM, has a potential claim-scope defense. The interpretation of "about" will depend on the specification, prosecution history, and ordinary pharmaceutical formulation practice.

The dependent claims identify two buffer systems:

  • Citric acid plus sodium citrate; and
  • Citric acid plus tromethamine.

Those alternatives do not limit claim 1 unless a product is being assessed against claims 4 or 5.

Stability limitation

The less-than-0.5% degradation requirement is unusually important. It is a performance limitation, not merely an ingredient limitation. A competing product may contain the same active, ethanol, water, and buffer but avoid claim 1 if it cannot be shown to meet the specified accelerated-stability result.

The limitation raises evidentiary questions:

  • Which degradation products count?
  • Is degradation measured in the liquid formulation, the extracted wipe, or the packaged product?
  • What assay method applies?
  • Does the test require the finished pouch and wipe substrate?
  • Is the result measured at the end of three months or throughout storage?

These issues can materially affect infringement analysis.

What do claims 2 through 13 add?

Claim Additional limitation Commercial significance
2 Pouch inner lining is LLDPE Targets barrier and compatibility construction
3 Propylene glycol Covers a common humectant and solvent system
4 Citric acid and sodium citrate buffer Narrows buffer chemistry
5 Citric acid and tromethamine buffer Alternative buffer chemistry
6 Alcohol approximately 53.7%-57.3% w/w; water ratio approximately 40:60 to 60:40 Targets a narrower solvent window
7 Alcohol approximately 53.7%-57.3%; buffer approximately 0.2%-0.5%; water to 100% Provides a more detailed formulation profile
8 Claim 3 formulation plus propylene glycol at approximately 2%-4% Covers a likely commercial formulation range
9 Method of treating hyperhidrosis with the wipe Creates use-based infringement exposure
10 Alcohol comprises ethanol Aligns with common commercial implementation
11 Preservative Covers preserved formulations
12 Additive Broad but specification-dependent
13 Enumerated wipe materials Covers multiple substrate formats

Claims 6-8 contain drafting complexity. Claim 6 refers to an alcohol-water ratio of approximately 40:60 to 60:40 while also specifying alcohol at approximately 53.7%-57.3% w/w. Claim 7 and claim 8 use a clearer percentage formulation structure. In litigation, the relationship between these limitations could affect claim construction and written-description arguments.

What formulations are protected by US 8,618,160?

The strongest commercial coverage is directed to a formulation with the following profile:

  • Glycopyrrolate or glycopyrronium salt at a topical concentration within 0.25%-6% w/w.
  • Ethanol as the alcohol.
  • Water as the co-solvent.
  • Approximately 53.7%-57.3% w/w ethanol.
  • Approximately 0.2%-0.5% buffer.
  • pH near 4.5.
  • Buffer concentration of approximately 10-20 mM.
  • Optional propylene glycol at approximately 2%-4%.
  • Individually packaged saturated cloth.
  • Leakage-resistant pouch, potentially with an LLDPE inner layer.
  • Accelerated stability showing less than 0.5% degradation after three months at 40°C.

This profile overlaps materially with Qbrexza, whose active pharmaceutical ingredient is glycopyrronium tosylate and whose dosage form is an individually packaged topical cloth for primary axillary hyperhidrosis (FDA, 2018).

The claims do not expressly require a particular dose per cloth, cloth dimensions, total liquid loading, or axillary-only application. Those omissions expand potential coverage, although the product must still satisfy the active concentration, pH, buffer, vehicle, packaging, and stability limitations.

When does US Patent 8,618,160 lose exclusivity?

The patent has a nominal United States term extending into the late 2029-2030 period based on its priority and filing history. The controlling date is the USPTO patent-term record, including any patent-term adjustment, terminal disclaimer, or other term modification.

FDA regulatory exclusivity is separate from patent exclusivity. Qbrexza received FDA approval on June 18, 2018. Its five-year new chemical entity exclusivity period expired in June 2023, subject to the FDA’s regulatory records and any applicable exclusivity adjustments (FDA, 2018; FDA, 2024).

Exclusivity category Relevance
Patent term Main barrier created by US 8,618,160 and related patents
NCE exclusivity Five years from Qbrexza approval; no longer the principal barrier
Three-year approval exclusivity May apply to qualifying changes, studies, or supplements, but does not block all ANDA filings
Orphan exclusivity Not the principal Qbrexza pathway
Pediatric exclusivity Must be checked in FDA records; it can add six months to listed protection

What is the Orange Book status of US 8,618,160?

Qbrexza is listed in the FDA Orange Book under its approved active ingredient and dosage form. Orange Book patent listings can include formulation, method-of-use, and other patents identified by the NDA holder. The listing of a patent does not establish that every claim will survive validity review or that every generic product infringes.

For an ANDA applicant, a listed patent creates the possibility of:

  • Paragraph I certification if the patent is not listed as relevant;
  • Paragraph II certification if the patent has expired;
  • Paragraph III certification accepting delayed approval until expiration; or
  • Paragraph IV certification asserting that the patent is invalid, unenforceable, or not infringed.

A Paragraph IV notice can trigger a 45-day period for the NDA holder to file suit. A timely infringement action generally can impose a 30-month stay on ANDA approval under the Hatch-Waxman framework, subject to statutory exceptions and court action (21 U.S.C. § 355; FDA, 2024).

Which companies are challenging Qbrexza patent protection?

Publicly verifiable competitive risk should be separated into three categories:

  1. ANDA generic risk. A generic applicant must reproduce or legally bridge the topical wipe product and address listed patents and FDA product requirements.
  2. Alternative topical anticholinergic risk. A competitor can avoid glycopyrrolate claims by using a different active ingredient.
  3. Compounded-product risk. Compounded topical glycopyrrolate products may compete commercially but do not establish FDA-approved generic substitutability.

A generic competitor would face technical barriers beyond active-ingredient equivalence. These include wipe saturation, content uniformity, pouch compatibility, ethanol evaporation, preservative performance, pH control, degradation products, and stability in the final packaged configuration.

No biosimilar pathway applies. Glycopyrronium tosylate is a small-molecule drug, not a biologic. FDA competition would proceed through an ANDA or, for a materially different product, a 505(b)(2) application rather than a biosimilar application.

How strong is the patent estate for Qbrexza?

US 8,618,160 is strongest against a product that copies the full finished-product architecture. Its principal strengths are:

  • Multiple simultaneous formulation limitations.
  • A packaging requirement tied to product stability.
  • A quantitative accelerated-stability limitation.
  • Dependent claims covering ethanol, propylene glycol, buffer systems, LLDPE, and wipe materials.
  • A method claim linked to the claimed wipe.

Its weaknesses are equally specific:

  • A competitor may alter ethanol concentration or alcohol-water ratio.
  • A competitor may use a different buffer or pH.
  • A different active ingredient avoids the glycopyrrolate limitation.
  • A non-wipe topical dosage form may avoid the individually packaged wipe requirement.
  • The stability limitation can create proof and claim-construction disputes.
  • The "about" ranges and claim 6 ratio language may support indefiniteness, written-description, or noninfringement arguments depending on the intrinsic record.

The patent is therefore a targeted product patent, not a broad platform patent.

What manufacturing and intellectual-property barriers affect generic launch?

A generic wipe must satisfy both pharmaceutical and package-performance requirements. The main barriers are:

Formulation and analytical testing

The applicant must control glycopyrronium assay, impurities, pH, ethanol content, buffer concentration, and degradation under accelerated conditions. The less-than-0.5% degradation threshold creates a direct design target for any product that may fall within claim 1.

Pouch and substrate compatibility

LLDPE is claimed in dependent claim 2, but other pouch structures may still fall within claim 1 if they are leakage-resistant. The pouch must limit solvent loss and prevent migration or interaction between the formulation and package.

Product-specific bioequivalence

For a topical wipe, FDA may evaluate drug release, product performance, dose delivery, active distribution, and local exposure. A liquid topical product, cream, gel, or pump spray may not qualify as an ANDA equivalent to an individually packaged cloth.

Manufacturing know-how

The patent claims do not capture every manufacturing step. Separate trade secrets or patents may cover impregnation, sealing, pouch formation, sterilization or microbial control, drying control, and in-process testing. Those barriers can delay entry even when a design-around is available.

What patent litigation and settlement issues matter?

A Paragraph IV dispute would likely focus on four questions:

  1. Whether the accused product contains a glycopyrrolate compound within the claimed concentration.
  2. Whether its alcohol-water system satisfies the claimed range.
  3. Whether the final packaged wipe meets the pH, buffer, and degradation limitations.
  4. Whether the claim covers the accused pouch and wipe construction after claim construction.

A settlement could provide a licensed launch date before patent expiry, an authorized-generic arrangement, or restrictions on formulation and manufacturing. A settlement date alone would not establish claim validity or infringement. Any current settlement or litigation position must be checked against PACER, FDA Orange Book updates, and USPTO records.

How does US 8,618,160 compare with alternative hyperhidrosis products?

Product category Active Dosage form Relationship to US 8,618,160
Qbrexza Glycopyrronium tosylate Individually packaged cloth Closest commercial overlap
Aluminum chloride products Aluminum chloride Solution, roll-on, or pad Generally outside glycopyrrolate limitation
Oral anticholinergics Glycopyrrolate or oxybutynin Tablet or capsule Outside wipe and topical-package limitations
Topical oxybutynin Oxybutynin Gel or other topical form Avoids glycopyrrolate limitation
Botulinum toxin Botulinum toxin Injectable biologic Outside claim scope and pathway
Compounded glycopyrrolate Glycopyrrolate Cream, solution, or wipe May implicate active and use limitations, but not necessarily all claim 1 elements

Key Takeaways

  • US 8,618,160 is a targeted patent covering a stable, individually packaged glycopyrrolate hyperhidrosis wipe.
  • Claim 1 requires every core element: active concentration, alcohol-water ratio, pH, buffer concentration, pouch, and accelerated stability.
  • Claims 2-8 and 10-13 narrow protection around LLDPE, ethanol, propylene glycol, buffer systems, formulation percentages, preservatives, additives, and wipe materials.
  • Claim 9 creates method-of-treatment exposure for topical use of the claimed wipe.
  • The patent does not cover all glycopyrronium products or all hyperhidrosis therapies.
  • Qbrexza is the principal commercial product aligned with the claimed architecture.
  • NCE exclusivity expired in 2023; patent and Orange Book barriers remain the more relevant generic-entry issues.
  • No biosimilar pathway applies because glycopyrronium tosylate is a small molecule.
  • The most practical design-around strategies involve changing the active ingredient, dosage form, vehicle ratio, buffer, pH, packaging, or stability profile.
  • The nominal patent term extends into the late 2029-2030 period, subject to the official USPTO term record.

FAQs

Can a glycopyrrolate gel infringe US Patent 8,618,160?

A gel would generally avoid the individually packaged wipe limitation unless it is delivered on a claimed wipe. It could still implicate other patents in the broader glycopyrrolate or Qbrexza estate.

Does using glycopyrronium bromide instead of glycopyrronium tosylate avoid the patent?

Not necessarily. Claim 1 uses the broader phrase "glycopyrrolate compound." A different salt may remain within the claim if all other limitations are satisfied.

Can a generic use a foil pouch instead of an LLDPE-lined pouch?

Potentially. Claim 2 specifically requires an LLDPE inner lining, but claim 1 requires only a leakage-resistant pouch. A foil pouch could avoid claim 2 while still raising claim 1 issues.

Does a pH of 5.0 avoid the patent?

It may provide a design-around position, but the answer depends on how "about 4.5" is construed and whether the formulation meets the other limitations.

Is a compounded glycopyrrolate wipe automatically an equivalent generic to Qbrexza?

No. Compounded status does not establish FDA therapeutic equivalence, ANDA substitutability, or freedom from patent infringement.

References

  1. Food and Drug Administration. (2018). Qbrexza (glycopyrronium) cloth, 2.4%: Prescribing information. U.S. Department of Health and Human Services.

  2. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, commonly known as the Orange Book. U.S. Department of Health and Human Services.

  3. United States Patent and Trademark Office. (2013). U.S. Patent No. 8,618,160: Glycopyrrolate compositions and methods of use thereof. U.S. Department of Commerce.

  4. Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 355.

  5. Drug Price Competition and Patent Term Restoration Act of 1984, Pub. L. No. 98-417, 98 Stat. 1585.

More… ↓

⤷  Start Trial


Drugs Protected by US Patent 8,618,160

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Journey QBREXZA glycopyrronium tosylate CLOTH;TOPICAL 210361-001 Jun 28, 2018 RX Yes Yes ⤷  Start Trial ⤷  Start Trial Y TOPICAL TREATMENT OF PRIMARY AXILLARY HYPERHIDROSIS IN ADULTS AND PEDIATRIC PATIENTS 9 YEARS OF AGE AND OLDER ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 8,618,160

PCT Information
PCT FiledOctober 17, 2008PCT Application Number:PCT/US2008/011907
PCT Publication Date:April 23, 2009PCT Publication Number: WO2009/051818

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.